艾迪联合TACE介入治疗原发性肝癌的临床研究  

Clinical research on treatment of Aidi combined with TACE interventional therapy for primary hepatic carcinoma

作　　者：郭梦安 徐美华[2] 胡奇军[3] 

机构地区：[1]益阳医学高等专科学校附属医院内科,湖南益阳413000 [2]中南大学湘雅医院消化内科,湖南长沙410008 [3]江西中医药大学人文学院,江西南昌330007

出　　处：《中国当代医药》2016年第26期37-39,共3页China Modern Medicine

基　　金：湖南省中医药科研计划项目(201291)

摘　　要：目的探讨艾迪联合经导管肝动脉化疗栓塞方法 （TACE）治疗原发性肝癌（PHC）的临床效果,为PHC患者提供一种安全、有效的治疗模式。方法将2012年1月~2015年10月本院住院的71例PHC患者随机分为两组,其中36例采用艾迪联合TACE介入治疗为研究组,35例仅采用TACE介入治疗为对照组,比较两组患者的临床疗效和不良反应等。结果研究组有效率为77.78%,明显高于对照组的48.57%,差异有统计学意义（P〈0.05）;两组AFP等实验室指标、生存率比较,差异有统计学意义（P〈0.05）。结论艾迪联合TACE介入治疗PHC从疗效、AFP、不良反应等方面分析,优于单纯介入治疗,值得临床推广应用。Objective To explore the clinic value of Aidi combined with TACE interventional therapy for primary hepatic carcinoma（PHC）,in order to provide a safe and effective treatment model.Methods 71 cases with PHC hospitalized in the hospital from January 2012 to October 2015 were randomly divided into two group,Patients treated by Aidi combined with TACE interventional therapy were selected as research group（n=36） and TACE interventional therapy alone as control group（n=35）.The clinic effects and adverse reactions and so on between two groups were compared.Results The difference had statistical significance in effect rate（research group of 77.78%,control group of 48.57%）,AFP and survival rate between two groups（P〈0.05）.Conclusion The combined therapy of Aidi and TACE for patients with PHC is prior to alone TACE interventional therapy in effect,karnofsky performance status,AFP and adverse reactions and so on,which is worthy of popularization and application in clinic.

关 键 词：艾迪 原发性肝癌 经导管肝动脉化疗栓塞方法介入治疗 

分 类 号：R735.7[医药卫生—肿瘤]